BiomericaBMRA
BMRA
About: Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Employees: 64
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
29% more capital invested
Capital invested by funds: $421K [Q4 2024] → $543K (+$122K) [Q1 2025]
14% more funds holding
Funds holding: 21 [Q4 2024] → 24 (+3) [Q1 2025]
3.13% less ownership
Funds ownership: 8.36% [Q4 2024] → 5.23% (-3.13%) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
50% less call options, than puts
Call options by funds: $33K | Put options by funds: $66K
Research analyst outlook
We haven’t received any recent analyst ratings for BMRA.
Financial journalist opinion
Based on 3 articles about BMRA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Mr. Chin brings over 20 years of financial experience across public and private healthcare organizations Mr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financing Mr.
Neutral
GlobeNewsWire
1 week ago
Biomerica's inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced diagnostic-guided therapies, today announced that data from its pivotal clinical trial evaluating the inFoods® IBS test in treating IBS sufferers has been published in the June 2025 issue of Gastroenterology , the official journal of the American Gastroenterological Association and the highest-impact publication in the GI field.
Neutral
GlobeNewsWire
3 weeks ago
Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System
IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), an innovator in diagnostic-guided therapy, today announced compelling real-world results demonstrating the effectiveness of its inFoods® IBS product, along with the launch of a proprietary real-time patient feedback system to enhance symptom tracking and improve patient outcomes.
Neutral
GlobeNewsWire
1 month ago
PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement
- Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test.
Neutral
GlobeNewsWire
1 month ago
United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Detection of H. pylori Infection
IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Helicobacter pylori (H. pylori) infection across the UAE—a region where gastrointestinal diseases are a growing public health concern.
Neutral
GlobeNewsWire
1 month ago
United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Disease Test for Early Detection of Kidney Damage
IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel® Kidney Disease (Microalbumin) Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This key regulatory milestone enables Biomerica to offer its innovative test across the UAE, a region facing a high burden of chronic kidney disease (CKD).
Neutral
GlobeNewsWire
1 month ago
Biomerica Announces Reverse Stock Split
IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, today announced that it will implement a 1-for-8 reverse stock split of the issued and outstanding shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m.
Neutral
GlobeNewsWire
3 months ago
Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn's Disease and Ulcerative Colitis
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that its food intolerance products for Crohn's Disease and Ulcerative Colitis have achieved CE-marking under the European Union's new In Vitro Diagnostic Medical Devices Regulation (IVDR – 2017/746).
Neutral
GlobeNewsWire
3 months ago
Biomerica's inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal
IRVINE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that patients with Irritable Bowel Syndrome (IBS) may experience significant relief from abdominal pain when following a dietary therapy created and guided by the inFoods® IBS blood test. The findings from a clinical trial published in Gastroenterology , demonstrate that participants who adhered to a personalized diet therapy based on the test results experienced greater symptom improvement compared to those following a sham (placebo) elimination diet.
Positive
Benzinga
4 months ago
Biomerica Stock Trades 200% Higher After Prostate Screening Test Receives Approval
Biomerica, Inc. BMRA stock is surging with a session volume of 139.2 million as per data from Benzinga Pro.
Charts implemented using Lightweight Charts™